The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
|Articles|April 7, 2022
Daily Medication Pearl: Valbenazine (Ingrezza)
Author(s)Saro Arakelians, PharmD
Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia.
Advertisement
Medication Pearl of the Day: Valbenazine (Ingrezza)
Indication: Valbenazine (Ingrezza) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.
Insight:
- Dosing:The initial dose is 40 mg once daily. After 1 week, increase the dose to the recommended dose of 80 mg once daily.
- Dosage forms: Capsules 40 mg.
- Adverse events: Most common adverse reaction (≥5% and twice the rate of placebo) is somnolence.
- Mechanism of action: The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown but is thought to be mediated through the reversible inhibition of VMAT2, a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
- Manufacturer: Neurocrine Biosciences
Advertisement
Related to this article
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
3
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
4
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
5